Ashkenazi Jewish genetic disorders

Familial Cancer

Volumn 3, Issue 3-4, 2004, Pages 201-206

  Charrow, Joel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Ashkenazi, Jewish, Jewish disorders, population screening

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL HYPERPLASIA; ARTICLE; BETA THALASSEMIA; BLOOM SYNDROME; CANAVAN DISEASE; CONGENITAL DEAFNESS; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; DYSAUTONOMIA; FAMILIAL MEDITERRANEAN FEVER; FANCONI ANEMIA; GAUCHER DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC DRIFT; GENETIC SCREENING; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLYCOGEN STORAGE DISEASE; HETEROZYGOSITY; HUMAN; JEW; MASS SCREENING; MUCOLIPIDOSIS; NIEMANN PICK DISEASE; PHENOTYPE; PRIORITY JOURNAL; TAY SACHS DISEASE; TORSION DYSTONIA;

DYSTONIA MUSCULORUM DEFORMANS; FEMALE; GAUCHER DISEASE; GENETIC DISEASES, INBORN; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENETICS, POPULATION; HUMANS; INCIDENCE; JEWS; MALE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TAY-SACHS DISEASE;

EID: 8544252461     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-004-9545-z     Document Type: Article

References (10)

1. Harris H. Enzyme polymorphisms in man. Proc R Soc London Ser B Biol Sci 1966; 164: 298-310.
2. Allison AC. Protection afforded by sickle cell trait against subtertian malarial infection. BMJ 1954; i: 290.
3. Grabowski GA. Gaucher disease: enzymology, genetics, and treatment. In Harris H, Hirschhorn K (eds): Advances in Human Genetics. New York: Plenum Press 1993; 377-441.
4. Charrow J, Andersson H, Kaplan P et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144: 1-9.
5. Gravel RA, Kaback MM, Proia RL et al. The GM2 gangliosidoses. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease, 8th edition. New York: McGraw-Hill 2001; 3827-76.
6. Jeyakumar M, Butters TD, Cortina-Borja M et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1999; 96: 6388-93.
7. Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Invest Drugs 2003; 4: 472-9.
8. Nemeth AH. The genetics of primary dystonias and related disorders. Brain 2002; 125: 695-721.
9. Bressman SB, de Leon D, Kramer PL et al. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol 1994; 36: 771-7.
10. Ekstein J, Katzenstein H. The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease. Adv Genet 2001; 44: 297-310.